Cover Image
市場調查報告書

腎臟癌治療藥的全球市場 (2015-2019年)

Global Kidney Cancer Drugs Market 2015-2019

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 264450
出版日期 內容資訊 英文 105 Pages
訂單完成後即時交付
價格
Back to Top
腎臟癌治療藥的全球市場 (2015-2019年) Global Kidney Cancer Drugs Market 2015-2019
出版日期: 2015年07月01日 內容資訊: 英文 105 Pages
簡介

腎臟癌是帶給腎臟細胞不良影響的疾病。RCC (腎細胞癌) 是成人中最常見的腎臟癌種類,在兒童的情況是威爾姆氏腫瘤為主。疾病的原因尚未明確。腎臟癌的症狀,常與其他腎臟疾病搞混,這導致延遲發現與患者的存活率低。多數情況,患者是在進行其他疾病檢驗時發現,普遍有偶然發現的傾向。腎臟被癌症侵入的細胞,透過外科手術去除,可完全治療這個疾病。還有數種藥物,可在早期發現的時候使用治療。TechNavio的分析師預測,全球腎臟癌治療藥市場預計從2014年到2019年以年複合成長率 (CAGR) 7.36%成長。

本報告以全球腎臟癌治療藥市場為主題,提供市場概要、市場發展推動因素、市場上課題,和那些的影響、進行開發平台分析的,以及各分子類型、各地區市場現況與展望調查分析、主要的供應商簡介彙整。

第1章 摘要整理

第2章 簡稱集

第3章 調查範圍

  • 市場概要
  • 提供產品

第4章 市場調查手法

  • 市場調查的過程
  • 調查手法

第5章 產品簡介

  • Nexavar
  • Avastin
  • Votrient
  • Afinitor/Votubia
  • Proleukin
  • Inlyta
  • Sutent
  • Torisel

第6章 簡介

第7章 疾病概要

  • 理解疾病
    • 腎臟癌的種類
    • 良性腎腫瘤
  • 風險因素
    • 生活方式及職業相關風險因素
    • 遺傳、先天的風險因素
    • 其他風險因素
  • 病因與發病
    • 先天的遺傳基因變異
    • 後天的遺傳基因變異
  • 徵兆與症狀
  • 診斷
    • 病歷和健康檢查
    • 研究所的檢驗
    • 影像檢查
    • 生物檢驗
  • 分期
    • TNM分類系統
  • 管理
    • 手術
    • 消除以及其他的局部治療
    • 放射治療 (RT)
    • 標的 (目標) 療法
    • 生物學的療法 (免疫療法)
    • 化療
  • 流行病學
  • 經濟負擔

第8章 開發平台分析

  • 開發平台候補相關主要的資訊
    • AGS-003
    • Rencarex
    • Cometriq
    • IMA901
    • AV-951
    • TroVax
    • MPDL3280A
    • Opdivo
    • Naptumomab Estafenatox
    • Carfilzomib

第9章 市場形勢

  • 市場概要
  • 市場規模與預測
  • 波特的五力分析

第10章 市場區隔,各分子類型

  • 小分子
  • 生物藥物

第11章 各地區區隔

第12章 購買條件

第13章 推動市場成長要素

第14章 推動因素與其影響

第15章 市場上課題

第16章 推動因素與課題的影響

第17章 市場趨勢

第18章 趨勢與其影響

第19章 業者情勢

  • 競爭模式
    • 主要消息
    • 吸收、合併
  • 市場佔有率分析,2014年
    • Bayer
    • Hoffmann-La Roche
    • GlaxoSmithKline
    • Novartis
    • Pfizer
  • 其他在及未來中值得注意的供應商

第20章 全球腎臟癌治療藥市場:主要調查結果

第21章 主要供應商分析 (主要的資訊、產業概要、各產業分類銷售額、各區域銷售額、產業策略、最近的趨勢、SWOT分析)

  • Bayer
  • F. Hoffmann-La Roche
  • GlaxoSmithKline
  • Novartis
  • Pfizer

第22章 本系列其他報告

圖表清單

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: IRTNTR6298

About Kidney Cancer

Kidney cancer also known as renal cancer affects the kidney cells. RCC is the most common form of kidney cancer in adults and Wilms' tumor in children. The exact cause of the disease is not yet known. The symptoms of renal cancer are often confused with other kidney disorders. This usually results in late stage detection of the disease, which leads to less chances of patient survival. In the majority of cases, it is diagnosed accidentally, when the patient undergoes checkups for other disorders.

Kidney cancer can be triggered by a number of factors including both lifestyle-related changes and genetic changes. The surgical removal of affected cancerous cells from the kidney provides a complete cure of the disease. A number of drugs are also available, which also help in the treatment of the disease when it is diagnosed at earlier stages.

Technavio's analysts forecast the global kidney cancer drugs market to grow at a CAGR of 7.36% over the period 2014-2019.

Covered in this Report

The report covers the present scenario and the growth prospects of the global kidney cancer drugs market for 2015-2019. To calculate the market size, the report considers the revenue generated from the sales of various approved therapies and off-label drugs used for the treatment of kidney cancer.

The three regions covered in the report are as follows:

  • Americas: US, Canada, Mexico, and Brazil
  • EMEA: UK, Germany, Italy, France, and Spain and Middle Eastern and African countries such Israel, South Africa, Egypt, Sudan, Kuwait, Saudi Arabia, Qatar, and UAE
  • APAC: Japan, China, Australia, Singapore, South Korea, and India.

Technavio's report, Global Kidney Cancer Drugs Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key Regions

  • Americas
  • APAC
  • EMEA

Key Vendors

  • Bayer
  • F. Hoffmann-La Roche
  • GlaxoSmithKline
  • Novartis
  • Pfizer

Other Prominent Vendors

  • Abbott Laboratories
  • Active Biotech
  • Amgen
  • Argos Therapeutics
  • ArQule
  • AVEO Pharmaceuticals
  • Bionomics
  • Bristol-Myers Squibb
  • Cerulean Pharma
  • Exelixis
  • Genentech
  • immatics biotechnologies
  • Immunicum
  • Ono Pharmaceutical
  • Onyx Therapeutics
  • Oxford BioMedica
  • Prometheus Laboratories
  • Seattle Genetics
  • Taiwan Liposome
  • TRACON Pharmaceuticals
  • Wilex

Market Driver

  • Increase in Patient Population
  • For a full, detailed list, view our report

Market Challenge

  • High Cost of Drugs
  • For a full, detailed list, view our report

Market Trend

  • Strategic Alliances
  • For a full, detailed list, view our report

Key Questions Answered in this Report

  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

Table of Contents

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

  • 03.1. Market Overview
  • 03.2. Product Offerings

04. Market Research Methodology

  • 04.1. Market Research Process
  • 04.2. Research Methodology

05. Product Profiles

    • 05.1.1. Nexavar
    • 05.1.2. Avastin
    • 05.1.3. Votrient
    • 05.1.4. Afinitor/Votubia
    • 05.1.5. Proleukin
    • 05.1.6. Inlyta
    • 05.1.7. Sutent
    • 05.1.8. Torisel

06. Introduction

07. Disease Overview

  • 07.1. Understanding the Disease
    • 07.1.1. Types of Kidney Cancer
    • 07.1.2. Benign Kidney Tumors
  • 07.2. Risk Factors
    • 07.2.1. Lifestyle and Job-related Risk Factors
    • 07.2.2. Genetic and Hereditary Risk Factors
    • 07.2.3. Other Risk Factors
  • 07.3. Etiology and Pathogenesis
    • 07.3.1. Inherited Gene Mutations
    • 07.3.2. Acquired Gene Mutations
  • 07.4. Signs and Symptoms
  • 07.5. Diagnosis
    • 07.5.1. Medical History and Physical Exam
    • 07.5.2. Lab Tests
    • 07.5.3. Imaging Tests
    • 07.5.4. Biopsy
  • 07.6. Staging
    • 07.6.1. TNM Staging System
  • 07.7. Management
    • 07.7.1. Surgery
    • 07.7.2. Ablation and Other Local Therapies
    • 07.7.3. Radiation Therapy
    • 07.7.4. Targeted Therapy
    • 07.7.5. Biologic Therapy (Immunotherapy)
    • 07.7.6. Chemotherapy
  • 07.8. Epidemiology
  • 07.9. Economic Burden

08. Pipeline Analysis

  • 08.1. Key Information on Pipeline Candidates
    • 08.1.1. AGS-003
    • 08.1.2. Rencarex
    • 08.1.3. Cometriq
    • 08.1.4. IMA901
    • 08.1.5. AV-951
    • 08.1.6. TroVax
    • 08.1.7. MPDL3280A
    • 08.1.8. Opdivo
    • 08.1.9. Naptumomab Estafenatox
    • 08.1.10. Carfilzomib

09. Market Landscape

  • 09.1. Market Overview
  • 09.2. Market Size and Forecast
  • 09.3. Five Forces Analysis

10. Market Segmentation by Molecule Type

  • 10.1. Small Molecules
  • 10.2. Biologics

11. Geographical Segmentation

12. Buying Criteria

13. Market Growth Drivers

14. Drivers and Their Impact

15. Market Challenges

16. Impact of Drivers and Challenges

17. Market Trends

18. Trends and Their Impact

19. Vendor Landscape

  • 19.1. Competitive Scenario
    • 19.1.1. Key News
    • 19.1.2. Mergers and Acquisitions
  • 19.2. Market Share Analysis 2014
    • 19.2.1. Bayer
    • 19.2.2. F. Hoffmann-La Roche
    • 19.2.3. GlaxoSmithKline
    • 19.2.4. Novartis
    • 19.2.5. Pfizer
  • 19.3. Other and Future Prominent Vendors

20. Global Kidney Cancer Drugs Market: Key Takeaways

21. Key Vendor Analysis

  • 21.1. Bayer
    • 21.1.1. Key Facts
    • 21.1.2. Business Overview
    • 21.1.3. Business Segmentation by Revenue 2014
    • 21.1.4. Business Segmentation by Revenue 2013 and 2014
    • 21.1.5. Geographical Segmentation by Revenue 2014
    • 21.1.6. Business Strategy
    • 21.1.7. Recent Developments
    • 21.1.8. SWOT Analysis
  • 21.2. F. Hoffmann-La Roche
    • 21.2.1. Key Facts
    • 21.2.2. Business Overview
    • 21.2.3. Business Segmentation
    • 21.2.4. Business Segmentation by Revenue 2012 and 2013
    • 21.2.5. Sales by Geography
    • 21.2.6. Business Strategy
    • 21.2.7. Key Information
    • 21.2.8. SWOT Analysis
  • 21.3. GlaxoSmithKline
    • 21.3.1. Key Facts
    • 21.3.2. Business Overview
    • 21.3.3. Business Segmentation by Revenue 2014
    • 21.3.4. Business Segmentation by Revenue 2013 and 2014
    • 21.3.5. Geographical Segmentation by Revenue 2014
    • 21.3.6. Business Strategy
    • 21.3.7. Recent Developments
    • 21.3.8. SWOT Analysis
  • 21.4. Novartis
    • 21.4.1. Key Facts
    • 21.4.2. Business Description
    • 21.4.3. Business Segmentation
    • 21.4.4. Revenue by Business Segmentation
    • 21.4.5. Revenue Comparison 2012 and 2013
    • 21.4.6. Sales by Geography
    • 21.4.7. Business Strategy
    • 21.4.8. Key Developments
    • 21.4.9. SWOT Analysis
  • 21.5. Pfizer
    • 21.5.1. Key Facts
    • 21.5.2. Business Overview
    • 21.5.3. Business Segmentation by Revenue 2014
    • 21.5.4. Business Segmentation by Revenue 2013 and 2014
    • 21.5.5. Geographical Segmentation by Revenue 2014
    • 21.5.6. Business Strategy
    • 21.5.7. Key Developments
    • 21.5.8. SWOT Analysis

22. Other Reports in This Series

List of Exhibits

  • Exhibit 1: Market Research Methodology
  • Exhibit 2: Types of Kidney Cancer
  • Exhibit 3: Types of Benign Kidney Tumor
  • Exhibit 4: Prevalence of Kidney Cancer by Gender
  • Exhibit 5: Global Kidney Cancer Drugs Market: Pipeline Portfolio
  • Exhibit 6: Global Kidney Cancer Drugs Market 2014-2019 ($ billions)
  • Exhibit 7: Segmentation of Global Kidney Cancer Drugs Market by Molecule Type
  • Exhibit 8: Segmentation of Global Kidney Cancer Drugs Market by Geography 2014
  • Exhibit 9: Major Drivers in Global Kidney Cancer Drugs Market
  • Exhibit 10: Major Challenges in Global Kidney Cancer Drugs Market
  • Exhibit 11: Major Trends of Global Kidney Cancer Drugs Market
  • Exhibit 12: Bayer: YoY Growth and Revenue of Nexavar 2010-2014 ($ millions)
  • Exhibit 13: F. Hoffmann-La Roche: YoY Growth and Revenue of Avastin 2010-2014 ($ millions)
  • Exhibit 14: GlaxoSmithKline: YoY Growth and Revenue of Votrient 2010-2014 ($ millions)
  • Exhibit 15: GlaxoSmithKline: Revenue of Votrient by Region 2010-2014 ($ millions)
  • Exhibit 16: Novartis: YoY Growth and Revenue of Afinitor 2010-2014 ($ millions)
  • Exhibit 17: Novartis: Revenue of Afinitor by Region 2012-2013 ($ millions)
  • Exhibit 18: Novartis: YoY Growth and Revenue of Proleukin 2012-2014 ($ millions)
  • Exhibit 19: Pfizer: YoY Growth and Revenue of Inlyta 2012-2014 ($ millions)
  • Exhibit 20: Pfizer: YoY Growth and Revenue of Sutent 2010-2014 ($ millions)
  • Exhibit 21: Global Kidney Cancer Drugs Market: Key Takeaways
  • Exhibit 22: Bayer: Business Segmentation by Revenue 2014
  • Exhibit 23: Bayer: Business Segmentation by Revenue 2013 and 2014 ($ billions)
  • Exhibit 24: Bayer: Geographical Segmentation by Revenue 2014
  • Exhibit 25: Business Segmentation of F. Hoffmann-La Roche 2013
  • Exhibit 26: F. Hoffmann-La Roche: Business Segmentation by Revenue 2012 and 2013
  • Exhibit 27: F. Hoffmann-La Roche: Sales by Geography 2013 (Pharmaceuticals Division)
  • Exhibit 28: F. Hoffmann-La Roche: Sales by Geography 2013 (Diagnostics Division)
  • Exhibit 29: GlaxoSmithKline: Business Segmentation by Revenue 2014
  • Exhibit 30: GlaxoSmithKline: Business Segmentation by Revenue 2013 and 2014 ($ billions)
  • Exhibit 31: GlaxoSmithKline: Geographical Segmentation by Revenue 2014
  • Exhibit 32: Novartis: Business Segmentation
  • Exhibit 33: Novartis: Revenue by Business Segmentation 2013
  • Exhibit 34: Novartis: Revenue by Business Segmentation 2012 and 2013 ($ millions)
  • Exhibit 35: Novartis: Revenue by Geographical Segmentation 2013
  • Exhibit 36: Pfizer: Business Segmentation by Revenue 2014
  • Exhibit 37: Pfizer: Business Segmentation by Revenue 2013 and 2014 ($ billions)
  • Exhibit 38: Pfizer: Geographical Segmentation by Revenue 2014
Back to Top